Vaccination with Brucella abortus recombinant in vivo-induced antigens reduces bacterial load and promotes clearance in a mouse model for infection
- PMID: 21412420
- PMCID: PMC3055878
- DOI: 10.1371/journal.pone.0017425
Vaccination with Brucella abortus recombinant in vivo-induced antigens reduces bacterial load and promotes clearance in a mouse model for infection
Abstract
Current vaccines used for the prevention of brucellosis are ineffective in inducing protective immunity in animals that are chronically infected with Brucella abortus, such as elk. Using a gene discovery approach, in vivo-induced antigen technology (IVIAT) on B. abortus, we previously identified ten loci that encode products up-regulated during infection in elk and consequently may play a role in virulence. In our present study, five of the loci (D15, 0187, VirJ, Mdh, AfuA) were selected for further characterization and compared with three additional antigens with virulence potential (Hia, PrpA, MltA). All eight genes were PCR-amplified from B. abortus and cloned into E. coli. The recombinant products were then expressed, purified, adjuvanted, and delivered subcutaneously to BALB/c mice. After primary immunization and two boosts, mice were challenged i.p. with 5 x 10⁴ CFU of B. abortus strain 19. Spleens from challenged animals were harvested and bacterial loads determined by colony count at various time points. While vaccination with four of the eight individual proteins appeared to have some effect on clearance kinetics, mice vaccinated with recombinant Mdh displayed the most significant reduction in bacterial colonization. Furthermore, mice immunized with Mdh maintained higher levels of IFN-γ in spleens compared to other treatment groups. Collectively, our in vivo data gathered from the S19 murine colonization model suggest that vaccination with at least three of the IVIAT antigens conferred an enhanced ability of the host to respond to infection, reinforcing the utility of this methodology for the identification of potential vaccine candidates against brucellosis. Mechanisms for immunity to one protein, Mdh, require further in vitro exploration and evaluation against wild-type B. abortus challenge in mice, as well as other hosts. Additional studies are being undertaken to clarify the role of Mdh and other IVI antigens in B. abortus virulence and induction of protective immunity.
Conflict of interest statement
Figures


Similar articles
-
Substantial Protective Immunity Conferred by a Combination of Brucella abortus Recombinant Proteins against Brucella abortus 544 Infection in BALB/c Mice.J Microbiol Biotechnol. 2019 Feb 28;29(2):330-338. doi: 10.4014/jmb.1811.10066. J Microbiol Biotechnol. 2019. PMID: 30609879
-
Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant.Infect Immun. 2001 Aug;69(8):4816-22. doi: 10.1128/IAI.69.8.4816-4822.2001. Infect Immun. 2001. PMID: 11447155 Free PMC article.
-
A combined subunit vaccine comprising BP26, Omp25 and L7/L12 against brucellosis.Pathog Dis. 2019 Nov 1;77(8):ftaa002. doi: 10.1093/femspd/ftaa002. Pathog Dis. 2019. PMID: 31971564
-
Brucellosis vaccines based on the open reading frames from genomic island 3 of Brucella abortus.Vaccine. 2018 May 17;36(21):2928-2936. doi: 10.1016/j.vaccine.2018.04.014. Vaccine. 2018. PMID: 29685597 Review.
-
What have we learned from brucellosis in the mouse model?Vet Res. 2012 Apr 13;43(1):29. doi: 10.1186/1297-9716-43-29. Vet Res. 2012. PMID: 22500859 Free PMC article. Review.
Cited by
-
Vaccination against a virus-encoded cytokine significantly restricts viral challenge.J Virol. 2013 Nov;87(21):11323-31. doi: 10.1128/JVI.01925-13. Epub 2013 Aug 14. J Virol. 2013. PMID: 23946461 Free PMC article.
-
Molecular cloning, purification and immunogenicity of recombinant Brucella abortus 544 malate dehydrogenase protein.J Vet Sci. 2016 Mar;17(1):119-22. doi: 10.4142/jvs.2016.17.1.119. Epub 2016 Mar 22. J Vet Sci. 2016. PMID: 27051349 Free PMC article.
-
Induction of systemic immunity through nasal-associated lymphoid tissue (NALT) of mice intranasally immunized with Brucella abortus malate dehydrogenase-loaded chitosan nanoparticles.PLoS One. 2020 Feb 6;15(2):e0228463. doi: 10.1371/journal.pone.0228463. eCollection 2020. PLoS One. 2020. PMID: 32027689 Free PMC article.
-
Safe Subunit Green Vaccines Confer Robust Immunity and Protection against Mucosal Brucella Infection in Mice.Vaccines (Basel). 2023 Feb 25;11(3):546. doi: 10.3390/vaccines11030546. Vaccines (Basel). 2023. PMID: 36992130 Free PMC article.
-
Screening of potential vaccine candidates against pathogenic Brucella spp. using compositive reverse vaccinology.Vet Res. 2021 Jun 2;52(1):75. doi: 10.1186/s13567-021-00939-5. Vet Res. 2021. PMID: 34078437 Free PMC article.
References
-
- Schurig G, Sriranganathan N, Corbel M. Brucellosis vaccines: past, present, and future. Vet Microbiol. 2002;90:479–496. - PubMed
-
- Elzer PH, Enright FM, Colby L, Hagius SD, Walker JV, et al. Protection aginst infection and abortion induced by virulent challenge exposure after oral vaccination of cattle with Brucella abortus strain RB51. Am J Vet Res. 1998;59:1575–1578. - PubMed
-
- Davis, DS, Elzer, PH Brucella vaccines in wildlife. Veterinary Microbiology. 2002;90:533–544. - PubMed
-
- Cook WE, Williams ES, Thorne ET, Kreeger TJ, Stout G, et al. Brucella abortus strain RB51 vaccination in elk. I. Efficacy of reduced dosage. J Wildl Dis. 2002;38:18–26. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical